Correction: Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.
作者信息
Lin Xiuli, Bao Shaorui, Yu Yueting, Huang Haiping, Shu Meichun
机构信息
Department of Infectious Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, China.
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, No.2 Fuxue Lane, Lucheng District, Wenzhou City, 325000, Zhejiang Province, China.
出版信息
J Health Popul Nutr. 2025 Jun 18;44(1):204. doi: 10.1186/s41043-025-00936-w.
Abstract
摘要
相似文献
1
Correction: Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.更正：代谢功能障碍相关脂肪性肝病患者的自我管理：影响因素及对再入院的影响
J Health Popul Nutr. 2025 Jun 18;44(1):204. doi: 10.1186/s41043-025-00936-w.
2
Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.代谢功能障碍相关脂肪性肝病患者的自我管理：影响因素及其对再入院的影响。
J Health Popul Nutr. 2024 Aug 31;43(1):134. doi: 10.1186/s41043-024-00618-z.
3
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.代谢功能障碍相关脂肪性肝病：肌肉与体重的故事。
World J Gastroenterol. 2025 May 28;31(20):105346. doi: 10.3748/wjg.v31.i20.105346.
4
Effect of high-intensity interval training on clinical parameters in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials.高强度间歇训练对代谢功能障碍相关脂肪性肝病患者临床参数的影响：一项随机对照试验的系统评价和荟萃分析
Eur J Gastroenterol Hepatol. 2025 Jul 1;37(7):789-798. doi: 10.1097/MEG.0000000000002964. Epub 2025 Mar 7.
5
Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States.模拟美国药物治疗非酒精性脂肪性肝炎相关肝病的健康和经济影响。
J Hepatol. 2025 Jan 18. doi: 10.1016/j.jhep.2025.01.009.
6
Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry.代谢功能障碍相关脂肪性肝病患者的瘙痒和疲劳：一项来自全球非酒精性脂肪性肝炎/代谢综合征相关脂肪性肝病注册研究的土耳其患者研究。
Clin Transl Gastroenterol. 2025 Apr 28;16(6):e00844. doi: 10.14309/ctg.0000000000000844. eCollection 2025 Jun 1.
7
Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.尿酸水平与代谢功能障碍相关及代谢和酒精相关/伴发的脂肪性肝病发生的关联：一项针对接受健康检查的日本参与者的研究
Endocr J. 2025 Jun 2;72(6):671-687. doi: 10.1507/endocrj.EJ24-0622. Epub 2025 Feb 26.
8
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease.慢性乙型肝炎合并脂肪性肝病患者的全因死亡率和特定病因死亡率。
J Hepatol. 2024 Dec 14. doi: 10.1016/j.jhep.2024.12.009.
9
Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact.中东和北非地区代谢功能障碍相关脂肪性肝病的流行病学趋势与负担：一项为期32年的健康影响分析
J Health Popul Nutr. 2025 Jun 18;44(1):207. doi: 10.1186/s41043-025-00973-5.
10
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.糖尿病患者的代谢功能障碍相关脂肪性肝病（MASLD）：筛查与早期干预的必要性。美国糖尿病协会共识报告
Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094.
本文引用的文献
1
Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.代谢功能障碍相关脂肪性肝病患者的自我管理：影响因素及其对再入院的影响。
J Health Popul Nutr. 2024 Aug 31;43(1):134. doi: 10.1186/s41043-024-00618-z.
Zotero 插件